Leqvio (Inclisiran) Compounding Legal Status

What Is Leqvio and How Does It Work?

Leqvio belongs to a new class of cholesterol-lowering drugs built on RNA interference technology. The active molecule, inclisiran, is a double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it specifically to hepatocytes 1. Once inside the liver cell, inclisiran silences the messenger RNA encoding PCSK9, a protein that normally degrades LDL receptors on the hepatocyte surface.

With PCSK9 production suppressed, more LDL receptors remain available to clear circulating LDL-C from the bloodstream. The GalNAc conjugation gives inclisiran a prolonged duration of action, which is why patients need only two doses in the first year and then one injection every six months. This mechanism is fundamentally different from PCSK9 monoclonal antibodies like evolocumab (Repatha) and alirocumab (Praluent), which bind circulating PCSK9 protein rather than preventing its synthesis 2.

The siRNA structure of inclisiran is what makes compounding both legally restricted and technically infeasible for standard compounding pharmacies. Unlike small-molecule drugs that can be synthesized with conventional chemistry, siRNA therapeutics require specialized oligonucleotide manufacturing platforms. This distinction matters for patients exploring alternatives.

FDA Approval History

The FDA approved Leqvio on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) in adults who require additional LDL-C lowering 3. The approval was based on three Phase III ORION trials.

ORION-10 enrolled 1,561 patients with ASCVD in the United States, and ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents across Europe and South Africa. In the pooled analysis, inclisiran 284 mg reduced LDL-C by approximately 51% at day 510 compared to placebo, with a time-averaged reduction of roughly 50.5% 1. These reductions were consistent regardless of baseline statin use.

ORION-9 focused on HeFH patients (N=482) and demonstrated a 39.7% reduction in LDL-C versus placebo at day 510 4. The European Medicines Agency (EMA) had previously authorized Leqvio in December 2020, making the U.S. approval a confirmatory regulatory step. Novartis submitted a supplemental Biologics License Application pathway, and the FDA classified inclisiran under the New Drug Application route (NDA 214012) because siRNA molecules fall below the size threshold for biologic classification under the BPCIA framework.

Why Leqvio Cannot Be Legally Compounded

Three independent regulatory barriers prevent lawful compounding of inclisiran. Each one alone would be sufficient to block compounding; together they form an airtight restriction.

The drug is not on the FDA shortage list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may only copy a commercially available drug product if that drug appears on the FDA Drug Shortage List. As of May 2026, inclisiran has no active shortage listing 5. Without a documented shortage, pharmacies have no legal basis to produce copies.

Active patent and exclusivity protections remain in effect. Novartis holds composition-of-matter and method-of-use patents on inclisiran that extend beyond 2035. The FDA also granted inclisiran regulatory exclusivity periods tied to its NDA approval. While 503B outsourcing facilities operate under slightly different rules than 503A pharmacies, neither pathway permits compounding of a patented, non-shortage drug without an explicit FDA determination.

The molecule itself is beyond compounding capability. Inclisiran is a 21-nucleotide sense strand and 23-nucleotide antisense strand with extensive chemical modifications, including 2'-O-methyl and 2'-fluoro substitutions, phosphorothioate linkages, and a GalNAc ligand. This level of synthetic complexity requires GMP oligonucleotide manufacturing. No traditional compounding pharmacy possesses the equipment, raw materials, or quality-control infrastructure to reproduce this molecule. Attempting to do so would produce a product of unknown identity and purity, creating serious patient safety risks.

What the Leqvio Label Specifies

The FDA-approved prescribing information for Leqvio contains several clinically relevant stipulations that prescribers and patients should understand 3.

The approved indication is as an adjunct to diet and maximally tolerated statin therapy for adults with HeFH or clinical ASCVD who need additional LDL-C lowering. Leqvio is not approved as monotherapy or as a first-line agent in place of statins. The label states the dosing regimen clearly: 284 mg administered subcutaneously at initiation, again at 3 months, then every 6 months thereafter. Each dose is a single 1.5 mL prefilled syringe.

A key label detail is the administration requirement. Leqvio must be given by a healthcare professional. It is not approved for self-administration or home injection, which distinguishes it from the PCSK9 monoclonal antibodies that patients can self-inject. This requirement means every dose involves an office or clinic visit.

The label lists injection site reactions as the most common adverse event, occurring in 8.2% of inclisiran-treated patients versus 1.8% on placebo in ORION-10 and ORION-11. These reactions were predominantly mild and transient. The label does not include a boxed warning, and no REMS (Risk Evaluation and Mitigation Strategy) is required 3.

Dr. Seth Baum, then-president of the American Society for Preventive Cardiology, stated at the time of approval: "Inclisiran represents a fundamentally different approach to PCSK9 inhibition. The twice-yearly dosing administered by a healthcare professional may address the adherence challenges we see with self-injected PCSK9 antibodies."

Safety Profile From Clinical Trials and Post-Market Data

The combined safety database from ORION-9, ORION-10, and ORION-11 included over 3,600 patients. Serious adverse events occurred at similar rates in inclisiran and placebo groups. In ORION-10 (N=1,561), the incidence of any serious adverse event was 22.4% with inclisiran versus 22.1% with placebo over 18 months 1.

Injection site reactions were the primary tolerability concern. Most were graded as mild (68%) or moderate (30%), with only 2% rated severe. No patients discontinued treatment due to injection site reactions in the key trials. Bronchitis, nasopharyngitis, and urinary tract infections appeared slightly more often in inclisiran-treated patients, though the differences were not statistically significant after multiplicity adjustment 1.

Liver transaminase elevations above three times the upper limit of normal occurred in 1.2% of inclisiran patients versus 1.3% of placebo patients, indicating no hepatotoxic signal. This is clinically relevant because inclisiran acts directly in hepatocytes. The FDA required Novartis to conduct the post-marketing ORION-4 cardiovascular outcomes trial (N=15,000), which is evaluating whether the LDL-C reductions observed with inclisiran translate into reductions in major adverse cardiovascular events 6.

Dr. Kausik Ray, lead investigator of ORION-11, noted: "The safety profile of inclisiran through 18 months of follow-up was broadly comparable to placebo, with injection site reactions being the principal differentiator."

How Leqvio Compares to Other PCSK9-Targeting Therapies

Patients and prescribers often ask how inclisiran fits alongside existing PCSK9 inhibitors. The comparison involves efficacy, dosing, route, and cost.

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies administered by subcutaneous self-injection every 2 to 4 weeks. Both reduce LDL-C by approximately 50 to 60% when added to statins, based on the FOURIER trial (evolocumab, N=27,564) and the ODYSSEY OUTCOMES trial (alirocumab, N=18,924) 7. Both trials demonstrated reductions in cardiovascular events.

Inclisiran achieves a similar magnitude of LDL-C lowering (approximately 50%) but with only two to three injections per year versus 13 to 26 for the antibodies. The trade-off is that inclisiran requires office-based administration, while the antibodies allow home self-injection. From a cost perspective, Leqvio launched with a list price of $3,250 per injection ($6,500 annually for two maintenance doses), which Novartis positioned as lower than the initial list prices of the PCSK9 antibodies.

One clinical difference worth noting: PCSK9 antibodies have completed cardiovascular outcomes trials showing event reduction, while inclisiran's outcomes trial (ORION-4) results are expected in 2026. The ACC/AHA cholesterol guidelines from 2018, updated in subsequent focused updates, include PCSK9 inhibitors as a treatment option for high-risk ASCVD patients who remain above LDL-C thresholds despite maximally tolerated statin and ezetimibe therapy 8.

Access, Coverage, and the Buy-and-Bill Model

Leqvio uses a buy-and-bill distribution model, meaning healthcare providers purchase the drug, administer it, and then bill the patient's insurance. This is typical for physician-administered injectables but unusual for cholesterol drugs, which have historically been pharmacy-dispensed oral or self-injectable medications.

Medicare Part B covers Leqvio because it is administered by a healthcare professional rather than self-administered (which would fall under Part D). Novartis established the Leqvio Complete program to assist with prior authorization, insurance verification, and patient copay support. For commercially insured patients, copay assistance may reduce out-of-pocket costs to as low as $0 per injection, though coverage specifics vary by plan 9.

The buy-and-bill model has implications for access. Practices must stock the medication, manage reimbursement workflows, and absorb the upfront cost before payer reimbursement. Smaller practices may find this logistically challenging, which can limit patient access in certain geographic areas.

What Patients Should Know About Off-Market or Compounded Versions

Any product marketed as "compounded inclisiran" or "generic Leqvio" is not legally produced and should be avoided. The FDA has not authorized any generic or compounded version of inclisiran. No ANDA (Abbreviated New Drug Application) for inclisiran appears in the FDA's Orange Book, and the technical barriers to siRNA compounding make any purported compounded product suspect in terms of both identity and sterility.

Patients who encounter online pharmacies or clinics offering compounded inclisiran should verify the source through the FDA's BeSafeRx program 10. The risks of using an unverified product include receiving an inert substance (no therapeutic effect), receiving a contaminated product (infection risk), and lacking the quality controls that GMP manufacturing provides.

For patients who cannot access or afford Leqvio, alternative FDA-approved PCSK9 inhibitors (evolocumab and alirocumab) are available with established cardiovascular outcomes data. Bempedoic acid (Nexletol) offers another non-statin LDL-C lowering option with a completed outcomes trial (CLEAR, N=13,970) showing a 13% reduction in major cardiovascular events 11.

Ongoing Regulatory Developments

Novartis continues to expand the inclisiran clinical program. ORION-4, a cardiovascular outcomes trial enrolling approximately 15,000 patients with pre-existing ASCVD, is the most significant ongoing study. Results are anticipated in 2026 and could reshape how inclisiran is positioned in treatment guidelines if a cardiovascular event reduction is confirmed 6.

The VICTORION program is exploring inclisiran in populations not covered by the current approval, including patients with homozygous familial hypercholesterolemia and pediatric patients. Regulatory submissions based on these trials could broaden the labeled indications in coming years.

On the compounding front, the FDA has not signaled any intent to place inclisiran on the shortage list or reclassify it in a way that would open compounding pathways. The agency's general posture toward complex biologics and oligonucleotide therapeutics has been to enforce strict manufacturing standards, and siRNA drugs face the same scrutiny as monoclonal antibodies in terms of compounding prohibitions.

Prescribers considering inclisiran for eligible patients should verify current formulary coverage, utilize the Novartis access support programs, and ensure their practice infrastructure supports the buy-and-bill model before initiating therapy. The recommended monitoring includes a lipid panel 90 days after the initial dose to confirm LDL-C response.